<DOC>
	<DOCNO>NCT02886689</DOCNO>
	<brief_summary>C.O.R.P.U.S . first French observatory care practice active inflammatory rheumatism child adult : rheumatoid arthritis , spondylarthropathy , idiopathic juvenile arthritis , establish auspex national health authority . Its goal document safety , effectiveness routine practice various therapy , include biotherapy , prescription non-prescription 5 year . A cohort constitute include new case active disease ( DAS 28 &gt; 3,2 , BASDAI &gt; 4 , failure methotrexate ) , without previous prescription biotherapy . Therefore , possible patient non expose biotherapy ( non indication , refusal , contraindication ) compare patient expose biotherapy , monitor adverse event occurrence well effectiveness routine practice time , accord prescription , maintenance switch various therapy .</brief_summary>
	<brief_title>C.O.R.P.U.S . : Observational Cohort Adult Child Inflammatory Arthritis France</brief_title>
	<detailed_description>Rational : Biotherapies , include anti-TNF alpha demonstrate effectiveness several randomize clinical trial . The long-term use clinical practice raise several question regard safety , risk-benefit ratio , actual advantage treatment real life routine practice . Moreover practice may considerably change , far increase number therapy make available market . On request form national health authority France , phase 4 study help monitor change strategy prescription , effectiveness safety drug . Objectives : 1. determine impact biotherapy prescription 3 category disease assess articular , functional quality life outcome , well drug consumption , monitor adverse event 2. determine place biotherapy sequence treatment patient Study design : open cohort study include patient 3 year continuously , last least 5 year form study start , annual prospective follow-up . C.O.R.P.U.S . first French observatory prescription ( non-prescription ) practice biotherapy first switch treatment . Sample : Patients recruit French network private rheumatologist , 40 university hospital rheumatology ward . Data collect : Socio-demographic , clinical parameter , function quality life know prognostic value - Exposed patient receive biotherapy - Non-exposed patient receive biotherapy : non indication , refusal , contraindication . Outcomes : radiographic joint lesion , function , adverse event , maintenance rate , drug consumption . Sample size : sample 1200 RA , 350 SPA 300 IJA recruit every year first 3 year . Adverse event : Any adverse event report national centre pharmacovigilance . IRB : protocol accept CCTIRS CNIL . Study monitoring : A scientific committee constitute charge respect aspects protocol , particularly regard safety A steering committee constitute include drug company representative marketing therapy , well representative Inserm .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<criteria>Diagnosis rheumatologist rheumatoid arthritis DAS score &gt; 3.2 , age onset hand foot xray within past 3 month never receive biotherapy Diagnosis rheumatologist spondylarthropathy ( ankylose spondylitis , psoriasic arthritis ) active disease hand foot ( peripheral ) spine ( axial ) xray within past 3 month Diagnosis rheumatologist idiopathic juvenile arthritis failure intolerance methotrexate xray within past 3 month receive previous biotherapy spondylarthropathy ankylose spondylitis , psoriasic arthritis</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>